News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
272,002 Results
Type
Article (14421)
Company Profile (282)
Press Release (257298)
Multimedia
Podcasts (57)
Webinars (9)
Section
Business (79611)
Career Advice (153)
Deals (13258)
Drug Delivery (35)
Drug Development (50525)
Employer Resources (31)
FDA (5757)
Job Trends (5147)
News (144604)
Policy (10044)
Tag
Academia (916)
Accelerated approval (4)
Adcomms (14)
Allergies (60)
Alliances (21760)
ALS (81)
Alzheimer's disease (893)
Antibody-drug conjugate (ADC) (127)
Approvals (5789)
Artificial intelligence (154)
Autoimmune disease (26)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (58)
Biotechnology (232)
Bladder cancer (68)
Brain cancer (27)
Breast cancer (206)
Cancer (1895)
Cardiovascular disease (140)
Career advice (135)
Career pathing (2)
CAR-T (145)
CDC (4)
Cell therapy (391)
Cervical cancer (9)
Clinical research (41745)
Collaboration (688)
Company closure (1)
Compensation (346)
Complete response letters (17)
COVID-19 (1050)
CRISPR (61)
C-suite (226)
Cystic fibrosis (87)
Data (2104)
Denatured (12)
Depression (47)
Diabetes (177)
Diagnostics (1315)
Digital health (3)
Diversity (3)
Diversity, equity & inclusion (9)
Drug discovery (100)
Drug pricing (32)
Drug shortages (3)
Duchenne muscular dystrophy (124)
Earnings (30357)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (49507)
Executive appointments (543)
FDA (6699)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (615)
Gene editing (123)
Generative AI (10)
Gene therapy (318)
GLP-1 (412)
Government (1101)
Grass and pollen (2)
Guidances (77)
Healthcare (6602)
HIV (12)
Huntington's disease (29)
IgA nephropathy (38)
Immunology and inflammation (114)
Immuno-oncology (5)
Indications (24)
Infectious disease (1123)
Inflammatory bowel disease (123)
Inflation Reduction Act (9)
Influenza (24)
Intellectual property (83)
Interviews (18)
IPO (7313)
IRA (11)
Job creations (865)
Job search strategy (127)
Kidney cancer (8)
Labor market (11)
Layoffs (223)
Leadership (4)
Legal (1393)
Liver cancer (34)
Longevity (8)
Lung cancer (261)
Lymphoma (139)
Machine learning (6)
Management (7)
Manufacturing (190)
MASH (78)
Medical device (2611)
Medtech (2612)
Mergers & acquisitions (6369)
Metabolic disorders (484)
Multiple sclerosis (64)
NASH (13)
Neurodegenerative disease (90)
Neuropsychiatric disorders (30)
Neuroscience (1415)
NextGen: Class of 2025 (2021)
Non-profit (855)
Now hiring (24)
Obesity (227)
Opinion (105)
Ovarian cancer (84)
Pain (52)
Pancreatic cancer (83)
Parkinson's disease (150)
Partnered (8)
Patents (173)
Patient recruitment (116)
Peanut (38)
People (25924)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14762)
Phase II (19420)
Phase III (12254)
Pipeline (1099)
Policy (66)
Postmarket research (852)
Preclinical (6265)
Press Release (30)
Prostate cancer (85)
Psychedelics (41)
Radiopharmaceuticals (220)
Rare diseases (362)
Real estate (1425)
Recruiting (12)
Regulatory (8866)
Reports (18)
Research institute (942)
Resumes & cover letters (17)
Rett syndrome (8)
RNA editing (10)
RSV (10)
Schizophrenia (75)
Series A (119)
Series B (79)
Service/supplier (1)
Sickle cell disease (49)
Special edition (13)
Spinal muscular atrophy (118)
Sponsored (13)
Startups (1984)
State (1)
Stomach cancer (5)
Supply chain (24)
Tariffs (14)
The Weekly (44)
Vaccines (244)
Venture capital (40)
Weight loss (115)
Women's health (17)
Worklife (2)
Date
Today (25)
Last 7 days (203)
Last 30 days (1025)
Last 365 days (18535)
2025 (10181)
2024 (20551)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (50)
Alaska (2)
Arizona (56)
Arkansas (5)
Asia (17599)
Australia (2979)
California (4751)
Canada (1346)
China (478)
Colorado (179)
Connecticut (175)
Delaware (137)
Europe (37791)
Florida (599)
Georgia (147)
Hawaii (1)
Idaho (16)
Illinois (285)
India (12)
Indiana (113)
Iowa (7)
Japan (122)
Kansas (66)
Kentucky (6)
Louisiana (4)
Maine (11)
Maryland (550)
Massachusetts (3813)
Michigan (86)
Minnesota (176)
Mississippi (2)
Missouri (25)
Montana (14)
Nebraska (4)
Nevada (20)
New Hampshire (14)
New Jersey (1174)
New Mexico (12)
New York (1267)
North Carolina (625)
North Dakota (6)
Northern California (2123)
Ohio (132)
Oklahoma (9)
Oregon (21)
Pennsylvania (888)
Puerto Rico (7)
Rhode Island (21)
South America (209)
South Carolina (6)
Southern California (1815)
Tennessee (29)
Texas (580)
United States (16185)
Utah (68)
Virginia (102)
Washington D.C. (36)
Washington State (413)
West Virginia (1)
Wisconsin (26)
272,002 Results for "skyhawk therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington’s Disease
June 17, 2025
·
4 min read
Press Releases
Skyhawk Therapeutics Presents at Huntington’s Disease Youth Organization HDYO International Congress 2025
March 17, 2025
·
2 min read
Business
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman
Skyhawk Therapeutics, Inc. announced the promotion of Clint Musil, former Chief Financial Officer of Skyhawk Therapeutics, to Chief Executive Officer and the appointment of Bill Haney, former Chief Executive Officer and Co-founder of Skyhawk Therapeutics, to Executive Chairman of the Board of Directors.
June 11, 2024
·
5 min read
Genetown
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases.
April 22, 2024
·
7 min read
Business
Ipsen, Skyhawk Ink Potential $1.8B Deal to Target RNA in Neuro Diseases
Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.
April 22, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington’s Disease Patient Trial
December 10, 2024
·
3 min read
Press Releases
Skyhawk Therapeutics to Present Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
October 17, 2024
·
2 min read
Press Releases
Skyhawk Therapeutics to Present Preclinical Data of SKY-1214 Combination Treatment in Hematologic Cancers at the 66th American Society of Hematology Annual Meeting
November 21, 2024
·
3 min read
Genetown
Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington’s Disease
Skyhawk Therapeutics today announced the Australian Human Research Ethic Committee (HREC) approval by Australian regulators for a clinical trial for Skyhawk’s SKY-0515 small molecule candidate targeting Huntington’s disease (HD).
October 23, 2023
·
3 min read
Drug Development
Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington’s Disease
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule RNA splicing modifiers, today announced that the Phase 1 multiple ascending dose (MAD) portion of its Phase 1 clinical study has now begun in Australia for the company’s SKY-0515 small molecule candidate targeting Huntington’s disease (HD).
February 28, 2024
·
3 min read
1 of 27,201
Next
